Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Documented progression from most recent line of therapy
1-3 prior lines of therapy
Measurable disease
Life expectancy ≥3 months

Prior treatment with Lenalidomide permitted if:

Best response achieved was ≥Partial Response (PR)
Patient was not refractory
Patient did not discontinue due to a Grade ≥3 related adverse event
Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression

Exclusion Criteria:

Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma
Active plasma cell leukemia
Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C